<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35487303</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>300</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PROTACs: Novel approach for cancer breakdown by breaking proteins.</ArticleTitle>
        <Pagination>
          <StartPage>120577</StartPage>
          <MedlinePgn>120577</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2022.120577</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0024-3205(22)00277-6</ELocationID>
        <Abstract>
          <AbstractText>Ubiquitination defects have been reported in various diseases, including neurodegenerative diseases, metabolic disorders and cancer. Balance between degradation and synthesis of the proteins to treat cancer can be managed by designing a chimeric molecule, known as Proteolysis Targeting Chimeric molecule (Lee, Kim et al. 2021). Proteolysis-targeting chimeras (PROTACs) acts as a tool for conducting therapeutic intervention. It eradicates or reduces the proteins that are responsible for causing diseases. Each PROTAC contains a target warhead, an E3 ligand and a linker. E3 ligases are recruited by these bifunctional molecules, and the Ubiquitin (Ub) Proteasome System (UPS) is used to target the degradation of specific proteins. As compared to inhibition, this degradation offers several advantages in the drug resistance, selectivity, and potency. Thus, numerous small molecule PROTACs are identified so far. In this review, the development of PROTACs, historical milestones, the biological mechanism, advantages and recent progress, and role of PROTAC in prostate cancer, breast cancer, non-hodgkin lymphoma, multiple myeloma, and malignant peripheral nerve sheath tumors are summarized.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Memon</LastName>
            <ForeName>Humera</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacy, Nirma University, Ahmedabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Bhoomika M</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacy, Nirma University, Ahmedabad, India. Electronic address: bgoyal@nirmauni.ac.in.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C049647">snake venom protein C activator</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.25.1</RegistryNumber>
          <NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002678" MajorTopicYN="Y">Chimera</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="Y">Multiple Myeloma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">Malignant peripheral nerve sheath tumors</Keyword>
        <Keyword MajorTopicYN="N">Multiple myeloma</Keyword>
        <Keyword MajorTopicYN="N">Non-Hodgkin lymphoma</Keyword>
        <Keyword MajorTopicYN="N">PROTACs</Keyword>
        <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        <Keyword MajorTopicYN="N">Protein degradation</Keyword>
        <Keyword MajorTopicYN="N">Ubiquitin proteasome system (UPS)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>19</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35487303</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2022.120577</ArticleId>
        <ArticleId IdType="pii">S0024-3205(22)00277-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
